Representations and Warranties of Alnylam. Except as provided in Schedule G, Alnylam represents and warrants to MedCo that as of the Effective Date:
Representations and Warranties of Alnylam. Alnylam represents and warrants to Licensee that, as of the Effective Date:
Representations and Warranties of Alnylam. Alnylam represents and warrants to Novartis:
Representations and Warranties of Alnylam. Alnylam represents and warrants to Roche that, as of the Effective Date:
Representations and Warranties of Alnylam. Alnylam represents and warrants to Monsanto that, as of the Effective Date:
Representations and Warranties of Alnylam. Except as provided in the Disclosure Schedule to this Section 10.1 (which Disclosure Schedule with respect to ALN-TTRsc is attached hereto as Schedule 10.1-1 and with respect to ALN-AT3 will be provided by Alnylam to Genzyme as part of the Option Data Package for ALN-AT3), Alnylam represents and warrants to Genzyme that, with respect to ALN-AT3, as of the Implementation Date, and, with respect to ALN-TTRsc, as of the Execution Date:
Representations and Warranties of Alnylam. 55 10.3 Representations and Warranties of Genzyme. 57
Representations and Warranties of Alnylam. Except as provided in Schedule 10.2, Alnylam represents and warrants to Genzyme that as of the Effective Date:
Representations and Warranties of Alnylam. Except as provided in Schedule 9.1 (Disclosure Schedule) with respect to each Global AT3 Licensed Product, Alnylam represents and warrants to Genzyme that as of the Implementation Date for such Global AT3 Licensed Product: CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. ALN-AT3 Global License Terms
Representations and Warranties of Alnylam. 9.2.1 As of the Effective Date Alnylam has sufficient legal and/or beneficial title and ownership of the Alnylam Patent Rights listed in Schedule 1.6A.1 to grant the licenses to such Alnylam Patent Rights granted to Kyowa Hakko pursuant to this Agreement.
